The Utility of MRD Testing for Myeloma Patient Treatment and Outcomes with Benjamin Derman, MD

The Utility of MRD Testing for Myeloma Patient Treatment and Outcomes with Benjamin Derman, MD
Event Description
CALL 347-637-2631 TO JOIN BY PHONE AND ASK QUESTIONS
Minimal Residual Disease (MRD) testing is a more sensitive way to test for remaining disease following myeloma treatment. Its use could change the way experts treat multiple myeloma now and in the future. MRD testing may help determine which patients should stay on treament or which patients are able to stop if they stay MRD negative for a long period of time. It may help prevent over or under treating patients.
In this show Benjamin Derman, MD of the University of Chicago shares what MRD testing is, how it's being used in clinical trials as a new clinical trial end point, what the FDA wants to see in clinical trial data, how it could be used to determine if treatment can stop based on a patient's status, why it's needed and when it should be used. He shares his MRD2STOP study and the results to date.
Patients can take advantage of the progress in MRD testing to truly personalize and optimize their care.
Thanks to our episode sponsor
We appreciate your donations to support the HealthTree Podcast for Multiple Myeloma.
Schedule & Agenda

Welcome, Announcements & Introduction

Welcome, Announcements & Introduction

A discussion with Dr. Derman about MRD testing and how it can help personalize care for myeloma patients.

A discussion with Dr. Derman about MRD testing and how it can help personalize care for myeloma patients.

Audience is able to call in to the radio show. Call 347-637-2631 and press 1 on your keypad to ask Dr. Derman questions about what was discussed during our interview today.

Audience is able to call in to the radio show. Call 347-637-2631 and press 1 on your keypad to ask Dr. Derman questions about what was discussed during our interview today.
Speakers & Moderators

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Benjamin Derman, MD, specializes in hematology and oncology. Dr. Derman is an expert in multiple myeloma and other plasma cell disorders, such as monoclonal gammopathy, amyloidosis, plasmacytoma, and POEMS syndrome. He also diagnoses and treats cancerous conditions and uses the most innovative techniques, including CAR T-cell therapy and stem cell transplantation to deliver long-term success for his patients. Along with his clinical practice, Dr. Derman remains committed to research. Currently, he is focused on identifying strategies that can lead to a possible cure for multiple myeloma, including using very sensitive tests that measure small amounts of residual cancer cells in the body called ‘minimal residual disease’ (MRD) to guide decision making. Dr. Derman is also investigating new methods and therapies designed to improve outcomes and quality of life for his patients. Additionally, he is interested in evaluating reasons for racial disparities in multiple myeloma outcomes to better understand and care for those patients. His work has been published in several peer-reviewed journals, including the Journal of Immunotherapy of Cancer, Blood, Blood Advances, Blood Cancer Journal, Leukemia and Lymphoma and British Journal of Haematology.
Have Any Questions?
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
Get In Touch With Us
1-800-709-1113
Support@healthtree.org






Get the Latest Multiple Myeloma Updates, Delivered to You.
By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.